Seagen and Lava enter licence agreement for solid tumour therapy
Lava will receive an upfront payment of $50m from Seagen for an exclusive worldwide licence to LAVA-1223.
Oncology
Latest in
Oncology
UK NICE grants approval for breast cancer drug combination
A CDK4/6 inhibitor, palbociclib is administered once a day as a pill in breast cancer patients.
Fennec’s hearing loss drug for cancer patients wins breakthrough FDA nod
Pedmark is indicated to treat cisplatin-induced ototoxicity in children and adolescents, the first approval of its kind for this group.
By
Sesen Bio and Carisma enter deal to combine businesses
The Sesen Bio and Carisma boards of directors have granted unanimous approval for the deal.
Abpro and Celltrion partner to develop antibody for cancer
Once Abpro completes in vitro studies, Celltrion will oversee the development of ABP 102.
Pfizer and CytoReason extend partnership for AI-driven drug discovery
The partnership would be worth up to $110m over the next five years.
BeiGene gets NICE recommendation for Waldenström Macroglobulinemia therapy
Brukinsa is a small molecule BTK inhibitor being assessed for treating various B-cell malignancies.
EC grants approval for BMS’ Opdualag to treat melanoma
In the Opdualag arm, median PFS was 6.7 months versus three months for subjects who were given nivolumab monotherapy.